The first patient was enrolled in the observational study on the treatment of cartilage hypoplasia by He Yu Medicine.

On the morning of June 23, Hutchison China MediTech announced on the Hong Kong Stock Exchange that its subsidiary, Shanghai Hutchison Pharmaceuticals Technology Co., Ltd., had completed the enrollment of the first patient in an observational study conducted in children with cartilage developmental disorders. This study will collect baseline information from patients for the research of the highly selective small molecule FGFR2/3 inhibitor ABSK061 in treating ACH. In March of this year, ABSK061 received approval for its IND application from the China National Medical Products Administration Drug Evaluation Center.